Adcendo, a biotech company pioneering the development of first- and potential best-in-class antibody-drug conjugates (ADCs) for cancers with a high unmet medical need, today announced two important Board changes and a key addition to the executive leadership team. Laura Shawver, Ph.D. will join as Chair of the Board of Directors, Roy Baynes, M.D., Ph.D. was appointed as an independent, non-executive director and Fang Z. Ni, Pharm.D. was named Chief Financial Officer. Dr. Shawver will replace John Haurum, M.D., D.Phil., who is stepping down from the Board.
“We are very grateful to John for his leadership and dedication in building Adcendo as a leading ADC company. Following the successful completion of our recent Series B financing, we continue to build a world-class team to turbocharge our operations and accelerate the advancement of our first-in-class ADC pipeline,” said Michael Pehl, Chief Executive Officer of Adcendo. “Laura’s visionary outlook and strategic acumen, combined with Roy’s wealth of clinical development experience and strong track record, and Fang’s financial and operations expertise, will be invaluable as we execute on all our corporate and clinical objectives. On behalf of the entire management team, it is a great privilege to work alongside all these high caliber individuals as we pursue our mission to transform the lives of patients with high unmet need cancers.”
As part of its global expansion strategy, Adcendo has established Adcendo U.S. Inc., and plans to open a Boston, MA office, reinforcing the company’s commitment to becoming a leading international ADC company and advancing clinical trials globally.
